We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
Cap. Flow
+$35.9M
Cap. Flow %
0.67%
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$59.7M
2
ODTX
Odyssey Therapeutics
ODTX
+$52.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$47.6M
4
COGT icon
Cogent Biosciences
COGT
+$47.6M
5
HUM icon
Humana
HUM
+$46.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$54.7M
2
DHR icon
Danaher
DHR
+$50.4M
3
ELVN icon
Enliven Therapeutics
ELVN
+$50.2M
4
BSX icon
Boston Scientific
BSX
+$48.8M
5
IRON icon
Disc Medicine
IRON
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.03%
2 Miscellaneous 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
101
Alnylam Pharmaceuticals
ALNY
$31.7B
$5.12M 0.09%
17,000
-102,000
-86% -$30.8M
PALI icon
102
Palisade Bio
PALI
$349M
$4.88M 0.09%
2,333,000
– –
ATAI icon
103
AtaiBeckley Inc
ATAI
$2.7B
$4.2M 0.08%
797,500
+450,500
+130% +$1.9M
UNH icon
104
CALL
UnitedHealth
UNH
$353B
$4.16M 0.08%
+10,000
New +$3.71M
PTCT icon
105
PTC Therapeutics
PTCT
$5.85B
$4.01M 0.07%
49,100
– –
AORT icon
106
Artivion
AORT
$1.31B
$3.93M 0.07%
175,000
+24,000
+16% +$671K
ELV icon
107
CALL
Elevance Health
ELV
$85.5B
$3.87M 0.07%
+10,000
New +$3.71M
NMRA icon
108
Neumora Therapeutics
NMRA
$261M
$3.64M 0.07%
+2,139,882
New +$4.07M
ACAD icon
109
Acadia Pharmaceuticals
ACAD
$5.02B
$3.47M 0.06%
+137,000
New +$3.01M
AMLX icon
110
Amylyx Pharmaceuticals
AMLX
$3.87B
$3.29M 0.06%
+183,400
New +$2.84M
TYRA icon
111
Tyra Biosciences
TYRA
$1.49B
$3.26M 0.06%
+102,000
New +$3.37M
RAPP
112
Rapport Therapeutics
RAPP
$2.34B
$3.19M 0.06%
+76,616
New +$2.82M
AGMB
113
AgomAb Therapeutics NV
AGMB
$649M
$2.5M 0.05%
+192,740
New +$2.17M
TARS icon
114
Tarsus Pharmaceuticals
TARS
$3.15B
$2.24M 0.04%
+35,581
New +$2.27M
ACRS icon
115
Aclaris Therapeutics
ACRS
$885M
$2.23M 0.04%
+421,500
New +$1.88M
CYTK icon
116
Cytokinetics
CYTK
$10B
$2.2M 0.04%
+25,800
New +$1.85M
NSPR icon
117
InspireMD
NSPR
$39.8M
$2.19M 0.04%
3,133,405
– –
OCUL icon
118
Ocular Therapeutix
OCUL
$2.28B
$2.16M 0.04%
+220,000
New +$1.99M
EVMN
119
Evommune Inc
EVMN
$480M
$2.14M 0.04%
+161,000
New +$3.74M
BLTE
120
Belite Bio
BLTE
$6.11B
$2.05M 0.04%
+13,300
New +$2.04M
OVID icon
121
Ovid Therapeutics
OVID
$547M
$2.01M 0.04%
+747,000
New +$1.93M
EPRX
122
Eupraxia Pharmaceuticals
EPRX
$441M
$1.78M 0.03%
+269,000
New +$1.85M
SLS icon
123
PUT
SELLAS Life Sciences
SLS
$2.67B
$1.37M 0.03%
+92,500
New +$639K
TRAW icon
124
Traws Pharma
TRAW
$9.07M
$1.01M 0.02%
1,203,260
+597,729
+99% +$824K
ADCT icon
125
ADC Therapeutics
ADCT
$146M
– –
-1,318,026
Closed -$4.94M
2 3 4
5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2026 Portfolio in Review

As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
  • OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
  • OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
  • OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
  • OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
  • OrbiMed opened 38 new positions and closed 23 in Q2 2026.
  • OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.